Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Perry, J. D.
Right arrow Articles by Gould, F. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perry, J. D.
Right arrow Articles by Gould, F. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 121-124
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Glycopeptide tolerance in bacteria causing endocarditis

John D. Perry*, Amanda L. Jones and Frances K. Gould

Department of Microbiology, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK

Glycopeptides have been recommended as therapy for endocarditis. MICs and MBCs of vancomycin and teicoplanin were compared for 100 isolates from patients with proven bacterial endocarditis. MICs were generally lower for teicoplanin and tolerance to both agents was common. Almost all isolates of enterococci were tolerant to both glycopeptides. Among the streptococci, 78% were tolerant to teicoplanin and 57% to vancomycin. Similar findings were demonstrated for staphylococci. Although isolates appear sensitive to glycopeptides, bactericidal activity cannot always be predicted. If a glycopeptide is indicated for treatment of endocarditis, combination therapy with a suitable aminoglycoside should be considered unless MBC testing can be performed.

* Corresponding author. Tel: +44-191-2843111, Ext. 26291; Fax: +44-191-2231224; E-mail: homeresearch{at}compuserve.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. M. Traczewski, B. D. Katz, J. N. Steenbergen, and S. D. Brown
Inhibitory and Bactericidal Activities of Daptomycin, Vancomycin, and Teicoplanin against Methicillin-Resistant Staphylococcus aureus Isolates Collected from 1985 to 2007
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1735 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Parcina, C. Wendt, F. Goetz, R. Zawatzky, U. Zahringer, K. Heeg, and I. Bekeredjian-Ding
Staphylococcus aureus-Induced Plasmacytoid Dendritic Cell Activation Is Based on an IgG-Mediated Memory Response
J. Immunol., September 15, 2008; 181(6): 3823 - 3833.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
K. L. Frank, J. L. del Pozo, and R. Patel
From Clinical Microbiology to Infection Pathogenesis: How Daring To Be Different Works for Staphylococcus lugdunensis
Clin. Microbiol. Rev., January 1, 2008; 21(1): 111 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. L. Frank, E. J. Reichert, K. E. Piper, and R. Patel
In Vitro Effects of Antimicrobial Agents on Planktonic and Biofilm Forms of Staphylococcus lugdunensis Clinical Isolates
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 888 - 895.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
I. Bourgeois, M. Pestel-Caron, J.-F. Lemeland, J.-L. Pons, and F. Caron
Tolerance to the Glycopeptides Vancomycin and Teicoplanin in Coagulase-Negative Staphylococci
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 740 - 743.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. L. French
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1107 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
G. Sakoulas, P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering Jr., and G. M. Eliopoulos
Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
J. Clin. Microbiol., June 1, 2004; 42(6): 2398 - 2402.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. C. Graham and F. K. Gould
Role of aminoglycosides in the treatment of bacterial endocarditis
J. Antimicrob. Chemother., March 1, 2002; 49(3): 437 - 444.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Vaudaux, P. Francois, B. Berger-Bachi, and D. P. Lew
In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus
J. Antimicrob. Chemother., February 1, 2001; 47(2): 163 - 170.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. H. Wilcox, P. Kite, K. Mills, and S. Sugden
In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm
J. Antimicrob. Chemother., February 1, 2001; 47(2): 171 - 175.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.